RMSL
REMSleep Holdings, Inc.0.0018
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
2.91MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
8-K
Founder passes; new CEO named
REMSleep Holdings reports founder Thomas Wood's passing on February 26, 2026, leaving CEO and Chairman vacancies. Effective March 2, Anita Michaels became Chairman; Jeffrey Marshall, sales veteran, took CEO with $60,000 base salary—rising to $120,000 post-$250,000 funding—and up to 7% equity on milestones. Anita retains full financial control initially. Leadership stabilized fast.
10-Q
Q3 FY2025 results
RemSleep Holdings posted Q3 revenue of $7.5k, down sharply y/y from $37.3k while flipping to a tiny gross profit of $7.4k from a $21.3k loss, yet a $2.3M operating loss ballooned on $2.2M related-party compensation (stock-for-services). Net loss hit $2.3M versus $278k y/y, with the gap to operating tied to interest and debt conversions offset by derivative gains. Cash fell to $344k after $373k YTD operating burn, propped by $254k in convertible notes (now $68k net); no capex so FCF not disclosed. Debt converts freely at deep discounts. Related-party deals dominate costs. DeltaWave sales just starting. Fierce competition shadows ramp-up.
10-Q
Q2 FY2025 results
RemSleep Holdings posted Q2 revenue of $4,824, down sharply 82.5% y/y from $27,594 yet marking first DeltaWave sales after ditching CPAP machines, with gross margin holding at 87.6% versus 78.5% prior (derived). Operating loss narrowed to $132,552 from $296,865 y/y, thanks to slashed development costs and a cheaper lease, but net loss widened to $287,772—beyond operating—due to $143,635 interest expense and debt losses offset by derivative gains. Cash dipped to $416K on $251K operating burn, propped by $204K in convertible notes at 10% with discounts; one prior note converted fully. Debt remains a drag.
10-Q
Q1 FY2025 results
RemSleep Holdings posted no revenue for Q1 ended March 31, 2025, down from $57,881 y/y, driving a $131K operating loss—wider than $124K last year—while net loss narrowed to $85K from $253K, thanks to a $208K gain on derivative fair value changes offsetting $76K interest and $86K debt issuance loss. Operating expenses dropped 22% to $131K, led by 36% lower G&A and slashed development costs after DeltaWave completion; lease ended early. Cash ticked up to $507K on $154K convertible notes (10%, various 2025 maturities), funding $110K ops burn. Issued 12M shares on cashless warrants. Controls falter on weak segregation.
10-K
FY2024 results
RemSleep Holdings posted FY2024 revenue of $117,185, down from $203,718 in 2023 due to fewer unit sales, yielding a slim $18,038 gross margin after normalized COGS versus last year's $738,113 inventory impairment drag. Operating loss narrowed to $794K from $1.8M as development costs on DeltaWave plunged 36% with FDA 510(k) clearance in July 2024, while professional fees and lease expenses also trimmed. Net loss improved to $1.08M, or $(0.00) per share on 1.48B diluted shares (anti-dilution from preferreds flagged). Cash burned $683K in operations but closed at $463K after $420K stock sales and $225K notes; capex hit $125K. No quarterly breakdowns disclosed. DeltaWave launches Q2 2025. Going concern looms large.
CBLL
CeriBell, Inc.
21.99+0.09
ELMD
Electromed, Inc.
29.88+0.28
INSP
Inspire Medical Systems, Inc.
115.51-3.75
NPCE
Neuropace, Inc.
15.88-0.04
NXL
Nexalin Technology, Inc.
0.81-0.01
RMD
ResMed Inc.
247.34-5.73
RMHI
Retrieve Medical Holdings Inc
2.82+0.02
SENS
Senseonics Holdings, Inc.
6.62-0.17
VMD
Viemed Healthcare, Inc.
7.26-0.11
VVOS
Vivos Therapeutics, Inc.
2.02+0.00